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ABSTRAK
Latar belakang: HbA1c berkorelasi dengan laju filtrasi 
glomerulus (LFG) dan tekanan darah diastolik (DBP). Tujuan 
utama penelitian ini adalah untuk mengevaluasi variabel 
biokimia dan klinis, dalam kaitannya dengan LFG pada pasien 
dengan diabetes mellitus tipe 2 (DMT2).
Metode: Penelitian ini merupakan studi retrospektif, 
longitudinal, dan deskriptif, melibatkan pasien DMT2, yang 
dirawat dari Januari hingga Desember 2014, di Clínica de 
Diabetes, Rumah Sakit Regional "Gral. Ignacio Zaragoza", 
ISSSTE, Kota Meksiko, Meksiko. LFG dihitung menggunakan tiga 
rumus: kolaborasi epidemiologi penyakit ginjal kronik (CKD-
EPI), Cockcroft-Gault, dan modification of diet in renal disease 
(MDRD), pada dua periode observasi, 3 dan 6 bulan. Hasilnya 
dibandingkan dengan uji t atau uji Wilcoxon-Mann-Whitney 
tergantung pada distribusi variabel. Uji Pearson digunakan 
untuk menganalisis korelasi antara LFG dengan setiap rumus 
dan variabel yang digunakan.
Hasil: Rerata usia adalah 56,5±11,3 tahun pada kelompok 
setelah 3 bulan (n=110) dan 57,1±13,8 tahun pada kelompok 
setelah 6 bulan (n=47). Pada kedua kelompok, formula dengan 
persentase terendah kasus CKD adalah CKD-EPI dan perbedaan 
dari formula ini memiliki korelasi positif yang signifikan dengan 
DBP. 
Kesimpulan: Rumus CKD-EPI menunjukkan persentase 
terendah kasus CKD dalam periode tindak lanjut pendek, 
dan perbedaan yang secara konsisten berkaitan dengan 
DBP, menegaskan pentingnya mengendalikan DBP untuk 
mengurangi evolusi menjadi CKD.
ABSTRACT
Background: HbA1c is correlated with the estimated 
glomerular filtration rate (eGFR) and diastolic blood 
pressure (DBP). Our main objective was to evaluate the trend 
of biochemical and clinical variables, in relation to the eGFR 
in patients with type 2 diabetes mellitus (T2DM).
Methods: This was a retrospective, longitudinal, and 
descriptive study, including patients with T2DM, who 
were cared for from January 2014 until December 2014, 
at the Clínica de Diabetes, Hospital Regional “Gral. Ignacio 
Zaragoza", ISSSTE, Mexico City, Mexico. eGFR was calculated 
using three formulas: the chronic kidney disease – 
epidemiology collaboration (CKD-EPI), Cockcroft-Gault, and 
modification of diet in renal disease (MDRD), during two 
periods of observation, 3 and 6 months. The results were 
compared by Student t tests or Wilcoxon-Mann-Whitney test 
depending on the variable distribution. Pearson correlation 
was employed to determine the relation between the eGFR 
determined with each formula and the analyzed variables.
Results: The mean age was 56.5±11.3 years in the group of 3 
months’ follow-up (n=110) and 57.1±13.8 years in the group 
of 6 months’ follow-up (n=47). In both groups, the formula 
with the lowest percentages of cases of CKD was CKD-EPI 
and the difference of this formula had a basal and final 
significant positive correlation with the DBP. 
Conclusion: The CKD-EPI formula showed the lowest 
percentages of cases of CKD in a short follow-up period, 
and its difference is consistently associated with the DBP, 
confirming the importance of controlling the later to 
mitigate the evolution to CKD.
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Lack of adherence to treatment involves large 
economic expenditures. Worldwide studies claim 
that one half of patients with type 2 diabetes 
mellitus (T2DM) do not adequately comply with 
their treatment and that fewer than 30% of patients 
change their habits or lifestyles.1 Compliance with 
adequate and intensive treatment is related with 
the delay in disease onset.2 
Measuring adherence presents difficulties 
because there is no unique method ascribed for 
it. The World Health Organization (WHO) defines 
adherence as the extent to which the behavior of 
a person corresponds to the recommendations 
agreed upon between the health professional 
and the patient, in terms of taking medications, 
monitoring a dietary treatment, and executing 
the programmed lifestyle changes.3 Some authors 
have demonstrated that the best adherence 
percentage achieved in chronic patients ranges 
between 50 and 75%.
Based on studies of T2DM, the latter is the leading 
cause of chronic kidney disease (CKD)4 even 
where it is not related with histological diabetic 
nephropathy.5 Incipient diabetic nephropathy 
is classically defined as increasing albuminuria, 
heralding a decline in the glomerular filtration 
rate (GFR). In fact, the prevalence of CKD in 
patients with T2DM is estimated to be 25–40% 
worldwide.6
Monitoring of renal function should be carried 
out by calculating the estimated GFR (eGFR), 
with three main techniques currently with 
widespread use: 1) the chronic kidney disease – 
epidemiology collaboration (CKD-EPI) equation, 
which generally results in lower prevalence of 
CKD and more accurate assessment of prognosis;7 
2) the Cockcroft-Gault formula, which indicates 
creatinine clearance, and 3) the modification 
of diet in renal disease (MDRD) formula, which 
evidences eGFR.8 
The formula developed by Cockcroft and Gault 
possesses a good correlation with the true GFR 
and is clinically useful in patients aged 20–100 
years; however, it has strong limitations in diabetes 
and should therefore be avoided, in addition its 
being overestimated in situations of advanced 
renal insufficiency and especially in obese and 
edematous patients.9 On the other hand, the 
MDRD combines nutrition and sociodemographic 
variables is recommended by the National Kidney 
Disease Education Program (NKDEP) to measure 
GFR in adult population.10 This formula tends to 
underestimate eGFR at higher levels, but performs 
better at lower eGFR (≤60 mL/min per 1.73 m2). 
Last, the CKD-EPI equation was developed in an 
effort to create a more precise formula than the 
MDRD, especially when the actual GFR is >60 ml/
min/1.73 m2.11.
HbA1c is correlated with the eGFR and diastolic 
blood pressure (DBP).12 In fact, a short term 
glycemic control can get reductions of blood 
pressure and GFR.13 This study aimed to describe 
the most consistent variables associated with 
deterioration in eGFR using the CKD-EPI, 
Cockcroft-Gault, and MDRD equations within a 
time-frame period of three and six months in 
patients with T2DM. 
METHODS
Patients
This was a retrospective, longitudinal, and 
descriptive study developed at the Clínica 
de Diabetes, Hospital Regional “Gral. Ignacio 
Zaragoza”, ISSSTE, Mexico City, Mexico. Patients 
with T2DM, of all ages, seen from January until 
December 2014, irrespective of metabolic control, 
were included in the study. We excluded patients 
not willing to participate in the study, and those 
who missed an appointment during the study 
were eliminated.
Following a 12 hours fasting, venous blood samples 
were taken in Vacutainer™ tubes for determination 
of glucose, total cholesterol, high-density lipoprotein 
cholesterol (HDL-ch), low-density lipoprotein-
cholesterol (LDL-ch), triglycerides, and uric acid 
(Hitachi 917® Autoanalyzer) and HbA1c. Capillary 
blood glucose was measured with a Precision® 
glucose monitor. Serum glucose was measured 
utilizing the glucose oxidase method, and HbA1c, 
with the turbidimetric inhibition immuno assay 
(TINIA) method (Roche). 
Clinical assessment
After their blood samples were taken, the patients 
ate breakfast from 9–10 a.m., and filled in the 
directed history (only at their first appointment), 
a survey of ingested kcal in the previous 24 hours, 
and a questionnaire on diabetes. Two hours post-
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breakfast glucose was measured, and the patients 
received education on diet, self-monitoring, 
exercise, American Diabetes Association (ADA) 
therapeutic targets, and chronic complications 
through classes and workshops.
Patients were measured (m) and weighed (kg) 
(Torino). Body mass index (BMI) was calculated 
as weight (kg) divided by height (m) squared. 
Blood pressure was measured with a mercury 
sphygmomanometer (Baumanometer, USA) after 
five min of rest.
A 24-hours dietary recall was used for this 
purpose. Diet was categorized within three 
choices: 1) consumption of 80–120% of the 
indicated kcal; 2) <80% of the indicated kcal, and 
3) >120% of the kcal indicated. Diet was classified 
as dichotomous whether this had or had not a 
balanced proportion of 50–60% carbohydrates, 
10–20% protein, and <30% fat. Calculated kcal 
were based on ideal weight minus 200 kcal/day if 
the patient was overweight.
Exercise (intensive walking, running, or cycling) 
was reported in days per week of physical 
activity and min/day. A specific activity was 
not prescribed due to the heterogeneous work 
schedule and physical conditions of the patients. 
Glomerular filtration rate
The GFR determination was made with the next 
aforementioned formulas:
CKD-EPI formula
eGFR = 141 × min(SCr/κ,1)α × max(Scr/κ,1)-1.209 × 
0.993Age × 1.018 [if female] × 1.159 [if black] 
Where SCr is serum creatinine (mg/dL), κ is 0.7 
for females and 0.9 for males, α is –0.329 for 
females and –0.411 for males, min indicates the 
minimum of Scr/κ or 1, and max indicates the 
maximum of Scr/κ or 1. 
Cockcroft and Gault formula
eGFR (mL/min) = [((140-age) × weight)/(72 × 
SCr)] × 0.85 if female 
Age is expressed in years, weight is expressed in 
kilograms, and SCr is expressed in mg/dL.
MDRD
eGFR (mL/min/1.73 m²) = 186 × SCr⁽⁻¹∙¹⁵⁴⁾ × 
Age⁽⁻⁰∙²⁰³⁾ × 0.742 (woman) × 1.210 (if black)
Where SCr = serum creatinine (mg/dL). 
Statistics
Quantitative or continuous variables were 
described by mean and standard deviation 
(SD) and, in some cases, by median and range. 
Qualitative variables were described by absolute 
frequency and percentage per modality. 
Quantitative variables were compared between 
groups by Student t test in case of normal 
distribution and the Wilcoxon-Mann-Whitney 
test otherwise. Missing data were not replaced. 
The analyzed population was defined as all 
patients who fulfilled all inclusion criteria with no 
major protocol deviations. Intra- and intergroup 
differences between baseline and values after 
three or six months were analyzed with the 
Student t test. Pearson correlation was employed 
to determine the relation between the GFR 
determined with each formula and the variables 
analyzed. All tests were performed with the SPSS 
v.20 statistical software program. 
Ethics
The Ethical and Research Committees of Ciprés 
Grupo Médico (CGM), code 2015/03, approved this 
study. The procedures followed were in accordance 
with the ethical standards of the General Health 
Law of Mexico and were subjected to the ethical 
and moral value judgments of the Declaration of 
Helsinki, updated in Fortaleza, Brazil. 
RESULTS
In the current study, mean age was 56.5±11.3 
years in the group of the three-month follow-up 
(n=110; 71 females and 39 males) and 57.1±13.8 
years in the six-month follow-up group (n =47; 28 
females and 19 males). Table 1 depicts the general 
characteristics of the patients. In Table 2, we 
illustrate the percentages of patients with renal 
failure by using each formula. In both groups, the 
formula with lowest percentages of cases of CKD 
was CKD-EPI.
Among all of the analyzed variables, those that 
maintained a significant correlation during both 
periods are presented in Table 3 and Figure 
1. As expected, age had a negative correlation 
with renal function; urea, creatinine, and uric 
acid all demonstrated all a significant negative 
correlation with the three formulas. In the lipid 
profile, there was a constant positive correlation 
between cholesterol and LDL and cholesterol and 
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triglycerides, and a negative correlation between 
triglycerides and HDL. Notoriously, there was a 
negative correlation between urea and albumin. 
Measurements for blood pressure, as expected, 
correlated. 
The whole population, at baseline, exhibited the 
following negative Pearson correlation between 
urea and the three formulas evaluated to calculate 
eGFR, CKD-EPI (r=–0.876; p≤0.001), MDRD (r=–
0.826; p≤0.001), and Cockcroft-Gault (r=–0.742; 
p≤0.001). When analyzing the same variables 
for creatinine, the same order was maintained 
(r=–0.797, p≤0.001), (r=–0.779; p≤0.001), and 
(r=0.669; p£0.001). For uric acid, the significant 
Follow-up period
3 months (n=110) 6 months (n=47)
Basal Final Basal Final
Albumin (g/dL) 4.1±0.4 4.2±0.3 4.2±0.3 4.2±0.2
BMI (kg/m2) 28.3±4.2 27.8±3.8 27.6±3.5 27.5±3.4
Ca (mg/dL) 9.2±1.2 9.3±1.2 9.1±0.4 9.2±0.3
Capillary Glucose am (mg/dL) 145.7±62.8 131.6±41.9 144.0±54.9 125.6±52.3
Cholesterol (mg/dL) 168.8±45.5 159.1±45.5 166.4±41.1 161.8±40.5
CKD-EPI (mL/min) 85.5±27.3 87.1±28.6 78.5±29.6 79.1±31.9
Cockcroft-Gault (mL/min) 96.0±53.5 103.1±50.8 84.0±35 82.6±39.7
Creatinine (mg/dL) 0.95±0.71 0.99±0.94 1.12±0.82 1.22±1.1
DBP (mm Hg) 78.1±7.4 76.9±7.5 80.8±9.1 75.4±6.8
Exercise (min/day) 25.2±21.9 27±18.7
Fat (%) 34.3±10 34.6±10.3 33.8±9.8 32.9±9.4
Globulin (g/dL) 3.3±2.8 3.1±1.8 2.9±0.4 2.9±0.3
Glucose (mg/dL) 145.6±62 135.9±45.8 136.1±48.7 132.7±42
HbA1c (%) 8.2±1.9 7.4±1.4 7.7±1.7 7.4±1.5
HDL-ch (mg/dL) 45.7±14.5 48.1±16.8 43.5±11.9 46.8±13.1
LDL-ch (mg/dL) 91.1±35.1 83.6±34.6 87.5±33 88.0±31
MAP (mm Hg) 88.2±20.5 83.2±26 91.9±16.1 86.0±19.4
MDRD (mL/min) 86.1±34.6 97.5±34.7 77.4±31 77.8±36.1
Muscle (%) 28.9±5.5 32.3±22.9 29.2±5 28.9±4.6
P (mg/dL) 3.7±0.8 3.7±0.5 3.5±0.5 3.6±0.5
SBP (mm Hg) 120.9±11.7 117.9±11.9 120±12.8 118.6±10.3
Triglycerides (mg/dL) 171.5±110.9 148.6±116.9 189.3±185.6 144.1±67.1
Urea (mg/dL) 39.7±24 40.5±24.8 44±23.7 44.9±30.5
Uric acid (mg/dL) 5.2±1.3 5.2±1.4 5.9±1.6 5.7±1.4
Visceral Fat (%) 10.6±3.4 10.6±3.3 10.9±3.4 10.5±3.8
Weight (kg) 71.6±13.3 70.7±12.4 69.7±11.5 69.1±11
Table 1. General characteristics of the studied groups
BMI: Body mass index, Ca: calcium, CKD-EPI: Chronic Kidney Disease-Epidemiology Collaboration, DBP: diastolic blood pressure, 
HDL-ch: High-density lipoprotein cholesterol, LDL-ch: Low-density lipoprotein cholesterol, MAP: mean arterial pressure, MDRD: 
Modification of Diet in Renal Disease, P: phosphorus, SBP: systolic blood pressure
Follow-up period (months)
3 6
Basal Final Basal Final
CKD-EPI 15.45 13.63 10.90 10.00
Cockcroft-Gault 16.36 16.36 12.20 15.45
MDRD 16.36 15.45 13.63 12.72
CKD-EPI: Chronic Kidney Disease-Epidemiology Collabora-
tion, MDRD: Modification of Diet in Renal Disease
Table 2. Percentages of patients with renal failure
negative correlations were only exhibited with 
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In the case of albumin, correlations were positive 
with MDRD (r=0.386; p=0.020), Cockcroft-Gault 
(r=0.379, p=0.023), and CKD-EPI (r=0.358; 
p=0.038). Among the equations, highest positive 
correlations were between CKD-EPI and MDRD 
(r=0.959; p≤0.001), second, between CKD-EPI 
and Cockcroft-Gault (r=0.883, p≤0.001), and last, 
between Cockcroft-Gault and MDRD (r=0.853; 
p≤0.001).
Through the multivariate lineal regression 
analysis in the group of three months follow-up, 
the variables with a significant prognosis for a 
final eGFR were age (p≤0.001 for both formulas), 
serum glucose (p=0.026 for MDRD and 0.015 
for CKD-EPI) and urea (p=0.002 for MDRD and 
≤0.001 for CKD-EPI). The same analysis in the 
group of six months showed that the initial value 
of urea was the only variable positively associated 
with the final eGFR calculated with CKD-EPI 
(p=0.008) and MDRD (p=0.005).
Follow-up period (months)
3 6
r p r p
Age and CKD-EPI -0.577 ≤0.001 -0.512 0.001
Age and Cockcroft-Gault -0.662 ≤0.001 -0.516 ≤0.001
Age and MDRD -0.540 ≤0.001 -0.415 0.012
Age and urea 0.351 ≤0.001 0.397 0.008
BMI and DBP 0.201 0.041 0.344 0.019
BMI and visceral fat 0.634 ≤0.001 0.685 ≤0.001
Capillary glucose (am) and serum glucose 0.587 ≤0.001 0.546 0.005
Cholesterol and fat 0.304 0.007 0.386 0.016
Comprehension goals and diet adherence 0.375 ≤0.001 0.401 0.005
Creatinine and muscle 0.366 0.002 0.410 0.023
DBP and CKD-EPI difference* 0.204 0.041 0.357 0.016
DBP and MBP 0.854 ≤0.001 0.893 ≤0.001
Diet adherence and diet comprehension 0.565 ≤0.001 0.556 ≤0.001
Diet comprehension and adherence 0.283 0.003 0.305 0.037
Diet comprehension and reaching goals 0.360 ≤0.001 0.330 0.024
Fat and muscle -0.568 0.048 -0.401 0.015
Glucose and HbA1c 0.652 ≤0.001 0.629 0.003
LDL and fat 0.361 0.002 0.367 0.017
SBP and DBP 0.296 0.002 0.398 0.006
SBP and MBP 0.750 ≤0.001 0.768 ≤0.001
BMI: Body mass index, CKD-EPI: CKD: chronic kidney disease, DBP: diastolic blood pressure, HDL-ch: high-density cholesterol, 
LDL-ch: low-density cholesterol, MBP: mean blood pressure, MDRD: Modification of Diet in Renal Disease, SBP: systolic blood 
pressure. *: Basal-final values.
Table 3. Significant correlations at 3 and 6 months
Figure 1. Significant correlations within a three and six 
month’s follow-up. BMI: body mass index, CG: Cockroft-
Gault, CGam: Capillary glucose am, CKD-EPI: Chronic Kidney 
Disease – Epidemiology Collaboration, DBP: diastolic blood 
pressure, DC: Diet Comprehension, dif: difference (basal-fi-
nal), eGFR: estimated glomerular filtration rate, GC: Goals in 
Comprehension, GI: Goals in Information, HDL: High-density 
lipoprotein, HypoG: Hypoglycemia, LDL: Low-density lipo-
proteins, MAP: mean arterial pressure, MDRD: Modification 
of Diet in Renal Disease, RG: Reaching goals, SBP: systolic 
blood pressure, S-M: Self-monitoring
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Finally, for the two periods, the only variable 
associated with an eGFR difference was DBP and 
CKD-EPI difference (basal–final), (three months: 
r=0.204, p=0.041; six months: r=0.357,  p=0.016). 
By contrast, the second measure of HbA1C had 
a negative correlation with the eGFR difference 
using the Cockcroft-Gault and MDRD (r=-0.245, 
p=0.011) formulas in the shorter period (three 
months).
DISCUSSION
In both groups, there was a predominance of 
female patients. This is in accordance with several 
publications that report more assiduous medical 
consultation from women than from men.14
In general, there were more significant 
correlations among variables within three-
months than the six-months period. This means a 
loss of power in the direct or indirect interactions 
that, otherwise, allows identification of stronger 
correlations despite the time involved. This 
finding is in concordance with a previous study 
designed to evaluate the effectiveness of a short-
term, community-based, individualized lifestyle 
intervention in patients with mild diabetes or 
hypertension who exhibited beneficial changes 
in activity, dietary, and clinical parameters.15 In 
a longer follow-up, another group demonstrated 
that, in order to sustain the impact of a community-
based comprehensive intervention for T2DM, 
improving and repeating the comprehensive 
strategy is greatly recommended, especially for 
patients with lower educational levels.16
Non-adherence to diabetes medications is 
associated with higher rates of mortality.17 In a 
previous publication of our group, we demonstrated 
that education programs in T2DM contribute to 
a decrease in HbA1c within six months, but an 
intensive program is more effective in reducing 
cholesterol and LDL.18 In this new approach 
within a shorter time period, we verified a positive 
correlation between diet comprehension and better 
adherence; this same diet comprehension facilitated 
reaching metabolic goals of control.
Ekinci et al19 suggest that aging, perturbations in 
blood pressure, and the development of intrarenal 
vascular disease may contribute to decreases 
in renal function independently of changes in 
albuminuria.19 It is likely that these data will 
remain constant in all countries.
It has been suggested that poor glycemic control 
may cause the risk of substantially increased 
blood pressure (BP) variability in subjects with 
diabetic nephropathy.20 In our two groups with 
different follow-up periods, this relationship was 
not found. The explanation is that this correlation 
was performed in all patients at each time and in 
each group, and not only in subjects with CKD. 
Classification of subject as CKD or non-CKD 
patients by different equations implies the 
assignment of a different risk of end-stage renal 
disease (ESRD); all-cause mortality, coronary 
artery disease, and stroke. For example, employing 
the MDRD equation in patients with T2DM 
underestimates GFR in patients with normal and 
high GFR21 and may be inaccurate in patients with 
normo-albuminuric patients with diabetes.22 In 
agreement with this statement, other authors 
have found that prevalence of CKD was lower 
using Cockcroft-Gault or CKD-EPI formulae than 
MDRD formulae.23,24 It is critical because being 
considered as CKD, low eGFR, and higher systolic 
blood pressure (SBP) are risk factors that are 
independently associated with peripheral arterial 
disease.25 Even more so, in the study of Fabbian 
et al24 the authors found that eGFR was <60 ml/
min/1.73 m2 in 15% of patients by MAYO, 26% 
by Cockcroft-Gault, 27% by MDRD186, 31.5% 
by MDRD175, and 30% by CKD-EPI. In contrast, 
in our patients, percentages were lower with 
the CKD-EPI formula. This difference could be 
attributed to the fact that the population that we 
studied was younger by about ten years.
Lifestyle interventions and good diabetes control 
are also linked with reduction of proteinuria and 
alleviation of CKD progression.26-29 In our patients, 
the exercise had a negative correlation with 
HbA1c only in the short follow-up period. With 
deeper analysis, a higher increase is appreciated 
in creatinine, urea, and uric acid after six months 
than after three months despite a better control 
of serum glucose, capillary glucose, HbA1c, lipid 
profile, and BP. 
Therapeutic management of diabetes is more 
challenging in patients with renal impairment. 
CKD vs non-CKD patients have less strict glycemic 
control.30 Greater emphasis should be placed on 
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the major risk factors, such as hypertension, 
smoking habits, and hyperlipidemia.31
This study has several limitations. First, we 
were not able to categorize CKD based on the 
new kidney disease: improving global outcomes 
(KDIGO) classification recommendations32 due 
to missing information about the albuminuria 
reports. Second, we did not estimate cystatin C, 
which is constantly produced and excreted by 
the kidney and has been recommended to be 
taken into account.33 Third, the cardiovascular 
risk score of each patient was not assessed, and 
subjects who suffered a cardiovascular event 
could have a lower renal function than those who 
did not. However, our aim was merely to show 
how the different formulae work in a clinical 
setting and their usefulness associated with the 
variables that show the most important changes 
and correlations. 
We conclude that, in a short evaluation period 
in patients with T2DM, the CKD-EPI formula 
shows the lowest percentages of cases of CKD. 
Besides, the eGFR difference calculated with 
CKD-EPI had a significant positive correlation 
with the DBP.
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